Oragenics, Inc. (OGEN) is an early-stage company aimed at fighting infectious diseases including COVID-19 and multidrug-resistant organisms. The company’s lead pipeline product is NT-CoV2-1 for the prevention of COVID-19 and its variants.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
OGEN stock price during the regular trading session of April 1, 2022, was $0.33 with a slight decline of 2.03%. Its price rose higher as of the writing in the aftermarket session by 12.5%.
OGEN: Events and Happenings
On April 1, 2022, OGEN announced the filing of Form 4 or Statement of changes in beneficial ownership of securities with SEC. On March 25, 2022, OGEN reported an unqualified audit opinion from its accounting firm, including an explanatory paragraph related to the continuation of the ability of the company as a going concern earlier disclosed in its Form 10-K. The statement was made with NYSE American LLC Company Guide Section 610(b).
OGEN: Key Financials
OGEN issued its consolidated financials on March 24, 2022, for the fiscal year 2021 ended on December 31, 2021. Some notable updates are cited below.
The company posted a grant revenue of $86.9 thousand during FY21 as compared to no revenues during the corresponding year 2020. Its revenue observed a 100% gain YoY.
Net loss basic and diluted for FY21 was $15.7 million or $0.14 per share corresponding to $26.4 million or $0.47 per share in the corresponding FY20. The company’s EPS gained considerably YoY.
On March 22, 2022, OGEN updated on the commencement of Good Laboratory Practice toxicology trials to assess the safety and immunogenicity profile of the company’s NT-CoV2-1 vaccine candidate in mammals. The study is intended to provide IND-enabling stats to help progress NT-CoV2-1 for human clinical studies. The company had made a contract with Frontage Laboratories for the conduction of the study, with interim outcomes expected in August 2022.
On March 10, 2022, OGEN reported its entry into a contract with KBI Biopharma, Inc. for the process transfer, process optimization, and cGMP production of its intranasal NT-CoV2-1vaccine candidate.
OGEN stock dipped by $0.52 or 60.7% in the last year due to slow progress made as a result of the pandemic. It leaped Friday’s aftermarket as the company reported SEC filing of Form 4. For the upcoming earnings release of the first fiscal quarter of 2022, the company’s EPS estimation is -$0.02.